Leadership Overview
Kyowa Kirin has 4 executives leading key functions including executive operations, clinical development, strategic medical affairs, and human capital management.
Driven by a commitment to antibody research, Kyowa Kirin advances therapeutic solutions in nephrology and oncology to improve patient outcomes globally through innovative engineering.
Driven by a commitment to antibody research, Kyowa Kirin advances therapeutic solutions in nephrology and oncology to improve patient outcomes globally through innovative engineering.
Leadership Roles at Kyowa Kirin
Yohei Yamazoe - Senior Chief of Staff for the Chief Executive Officer and the Chief Operating Officer
Yohei Yamazoe, the Senior Chief of Staff for the Chief Executive Officer and the Chief Operating Officer at Kyowa Kirin, manages high-level administrative workflows and strategic alignment between top leadership. Yamazoe facilitates communication across the executive suite, ensuring that corporate objectives in antibody research remain prioritized. By coordinating complex projects, the Senior Chief of Staff for the Chief Executive Officer and the Chief Operating Officer optimizes decision-making processes for the entire organization. Yohei Yamazoe monitors operational efficiency, providing critical support for the execution of global pharmaceutical initiatives. This role involves synthesizing data from various departments to inform the long-term vision of the company. Through rigorous oversight of internal communications and executive priorities, the Senior Chief of Staff for the Chief Executive Officer and the Chief Operating Officer maintains organizational focus on delivering specialized medical treatments to patients worldwide while supporting the broader mission of the firm.
Chizu Sato - Head of Global Clinical Operations Chief of Staff
Chizu Sato, the Head of Global Clinical Operations Chief of Staff at Kyowa Kirin, directs the execution of international clinical trials and research protocols. Sato oversees the integration of clinical data across diverse therapeutic areas, including nephrology and immunology. By managing cross-functional teams, the Head of Global Clinical Operations Chief of Staff ensures compliance with global regulatory standards while accelerating the development of antibody-based therapies. Chizu Sato coordinates resource allocation to support large-scale clinical programs, driving efficiency in the drug development pipeline. This leadership position requires constant collaboration with research scientists and external partners to maintain the integrity of clinical studies. Through the implementation of standardized operational procedures, the Head of Global Clinical Operations Chief of Staff facilitates the transition of innovative research into viable patient treatments. Sato secures the operational success of global clinical initiatives, directly impacting the company's ability to address unmet medical needs.
Kristen Stevens Sickle - Chief of Staff To Senior Vice President. Head of Strategic Initiatives, North America Medical Affairs
Kristen Stevens Sickle, the Chief of Staff To Senior Vice President. Head of Strategic Initiatives, North America Medical Affairs at Kyowa Kirin, architects the strategic direction for medical affairs within the North American market. Sickle drives the implementation of initiatives that bridge clinical research with patient care requirements. By aligning regional medical strategies with global corporate goals, the Chief of Staff To Senior Vice President. Head of Strategic Initiatives, North America Medical Affairs ensures that therapeutic advancements reach target populations effectively. Kristen Stevens Sickle manages complex stakeholder relationships, fostering collaboration between medical teams and commercial operations. This role involves analyzing market trends to refine the delivery of specialized pharmaceutical solutions. Through the oversight of strategic planning, the Chief of Staff To Senior Vice President. Head of Strategic Initiatives, North America Medical Affairs optimizes the impact of medical programs, supporting the expansion of the company's footprint in the competitive North American pharmaceutical landscape.
Shoko Itagaki - Global Chief People Officer, Corporate Planning Head
Shoko Itagaki, the Global Chief People Officer, Corporate Planning Head at Kyowa Kirin, directs human capital strategy and long-term corporate planning. Itagaki designs organizational structures that support the company's focus on antibody research and engineering. By fostering a culture of innovation, the Global Chief People Officer, Corporate Planning Head ensures that talent acquisition and development align with the evolving needs of the pharmaceutical industry. Shoko Itagaki integrates corporate planning with workforce management to drive sustainable growth across global operations. This leadership role involves collaborating with the executive team to define the company's future trajectory and operational priorities. Through the implementation of comprehensive talent management programs, the Global Chief People Officer, Corporate Planning Head enhances organizational agility. Itagaki maintains a focus on building high-performing teams capable of delivering complex medical solutions, ensuring that the workforce remains equipped to meet the challenges of the global healthcare market.
Explore Leadership Teams in Manufacturing
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines. Its portfolio spans oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, infectious diseases and rare diseases. The company invests heavily in research and development to develop innovative medicines and improve patient outcomes, with operations and a broad commercial presence worldwide.
Company Leadership GB
JZ
AT
BeOne Medicines is a global biotechnology and pharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative cancer treatments. Its research and development programs target hematologic malignancies and solid tumors, with a mission to expand access to effective cancer therapies worldwide.
Company Leadership
SC
ML
XW
Bliss GVS Pharma Limited is a global pharmaceutical company specializing in the manufacturing of a wide range of pharmaceutical products, including capsules, creams, injections, and various healthcare items. The company is recognized as the world's largest manufacturer of suppositories and pessaries, operating world-class facilities that prioritize quality and efficiency. Their mission focuses on discovering and rediscovering pharmaceutics to enhance well-being while increasing the accessibility of pharmaceuticals worldwide. The intended clients include healthcare providers and consumers seeking reliable and effective pharmaceutical solutions.
Company Leadership VD
DS
VR
AM
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Company Leadership SP
CS
NB
RI
Frequently Asked Questions Regarding Kyowa Kirin Top Executives and Leadership Team
Unlock more people and company data
